| A revised picture of the E2F transcriptional network and RB function O Stevaux, NJ Dyson Current opinion in cell biology 14 (6), 684-691, 2002 | 585 | 2002 |
| GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation O Nolan-Stevaux, J Lau, ML Truitt, GC Chu, M Hebrok, ... Genes & development 23 (1), 24-36, 2009 | 466 | 2009 |
| Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes M Korenjak, B Taylor-Harding, UK Binné, JS Satterlee, O Stevaux, ... Cell 119 (2), 181-193, 2004 | 323 | 2004 |
| Cell cycle-dependent and cell cycle-independent control of transcription by the Drosophila E2F/RB pathway DK Dimova, O Stevaux, MV Frolov, NJ Dyson Genes & development 17 (18), 2308-2320, 2003 | 299 | 2003 |
| Functional antagonism between E2F family members MV Frolov, DS Huen, O Stevaux, D Dimova, K Balczarek-Strang, ... Genes & development 15 (16), 2146-2160, 2001 | 203 | 2001 |
| Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies O Nolan-Stevaux, W Zhong, S Culp, K Shaffer, J Hoover, ... PloS one 7 (12), e50920, 2012 | 148 | 2012 |
| Distinct mechanisms of E2F regulation by Drosophila RBF1 and RBF2 O Stevaux, D Dimova, MV Frolov, B Taylor‐Harding, E Morris, N Dyson The EMBO journal, 2002 | 119 | 2002 |
| Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell–recruiting antibody optimized for cytotoxicity and cytokine release CL Zuch de Zafra, F Fajardo, W Zhong, MJ Bernett, US Muchhal, ... Clinical Cancer Research 25 (13), 3921-3933, 2019 | 105 | 2019 |
| Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma P Olson, GC Chu, SR Perry, O Nolan-Stevaux, D Hanahan Proceedings of the National Academy of Sciences 108 (49), E1275-E1284, 2011 | 90 | 2011 |
| Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors B Belmontes, DV Sawant, W Zhong, H Tan, A Kaul, F Aeffner, SA O’Brien, ... Science Translational Medicine 13 (608), eabd1524, 2021 | 58 | 2021 |
| The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer P Deegen, O Thomas, O Nolan-Stevaux, S Li, J Wahl, P Bogner, F Aeffner, ... Clinical Cancer Research 27 (10), 2928-2937, 2021 | 55 | 2021 |
| Retinoblastoma family 2 is required in vivo for the tissue-specific repression of dE2F2 target genes O Stevaux, DK Dimova, JY Ji, NS Moon, MV Frolov, NJ Dyson Cell Cycle 4 (9), 1272-1280, 2005 | 49 | 2005 |
| Measurement of cancer cell growth heterogeneity through lentiviral barcoding identifies clonal dominance as a characteristic of in vivo tumor engraftment O Nolan-Stevaux, D Tedesco, S Ragan, M Makhanov, A Chenchik, ... PloS one 8 (6), e67316, 2013 | 41 | 2013 |
| G1 cyclin-dependent kinases are insufficient to reverse dE2F2-mediated repression MV Frolov, O Stevaux, NS Moon, D Dimova, EJ Kwon, EJ Morris, ... Genes & development 17 (6), 723-728, 2003 | 39 | 2003 |
| Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes O Nolan-Stevaux, MC Truitt, JC Pahler, P Olson, C Guinto, DC Lee, ... Genes & cancer 1 (2), 125-141, 2010 | 36 | 2010 |
| Antibody constructs for CD70 and CD3 T Raum, C Blümel, W Deisting, P Hoffmann, R Lutterbüse, E Nahrwold, ... US Patent 10,851,170, 2020 | 20 | 2020 |
| Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody C de Zafra, M Balazs, F Fajardo, L Liang, W Zhong, A Henn, MJ Bernett, ... Blood 130, 500, 2017 | 17 | 2017 |
| Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway Y Shen, JS Eng, F Fajardo, L Liang, C Li, P Collins, D Tedesco, ... Journal for immunotherapy of cancer 10 (3), 2022 | 16 | 2022 |
| Heterodimeric antibodies that bind cd3 and cd38 JL Stevens, M Balazs, O Nolan-Stevaux, G Moore, J Desjarlais, ... US Patent App. 15/779,325, 2018 | 15 | 2018 |
| Abstract DDT02-03: AMG 509: A novel, humanized, half-Life extended, bispecific STEAP1 × CD3 T cell recruiting XmAb® 2+1 antibody O Nolan-Stevaux Cancer research 80 (16_Supplement), DDT02-03-DDT02-03, 2020 | 13 | 2020 |
